Schedule 13G ownership disclosure
Amylyx Pharmaceuticals Inc
Common Stock, $0.0001 par value per share · CUSIP: 03237H101
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLC
Shares: 8,952,365 · Class: 8.2%
- Joseph Edelman
Shares: 8,952,365 · Class: 8.2%
- Perceptive Life Sciences Master Fund, Ltd.
Shares: 8,952,365 · Class: 8.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-282838
- Form type
- SCHEDULE 13G/A
- Filer
- Amylyx Pharmaceuticals, Inc.
- CIK
- CIK 1658551
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership